Immune Complex Membranoproliferative Glomerulonephritis: Clinical Trials

2 trials for Immune Complex Membranoproliferative Glomerulonephritis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 1 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable1Completed 1
Phase 21Terminated 1

Follow Immune Complex Membranoproliferative Glomerulonephritis: new trials by email Literature Review of Immune Complex Membranoproliferative Glomerulonephritis trials Research Report on Immune Complex Membranoproliferative Glomerulonephritis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
Non contrast-enhanced magnetic resonance imaging - C3 Glomerulonephritis, C3 Glomerulopathy
Not applicableCompletedMario Negri Institute for Pharmacological Research72018-12-062021-11-26
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy
Phase 2TerminatedAlexion Pharmaceuticals, Inc.222018-06-202023-08-21

Narrower conditions

Glomerulonephritis, Membranoproliferative (2)

Broader conditions

Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Glomerulonephritis (2)  ·  Immune System Diseases (2)  ·  Kidney Diseases (2)  ·  Male Urogenital Diseases (2)  ·  Nephritis (2)  ·  Urogenital Diseases (2)  ·  Urologic Diseases (2)

Interventions

danicopan (1)

Sponsors

Alexion Pharmaceuticals, Inc. (1)  ·  Mario Negri Institute for Pharmacological Research (1)

Countries

Italy (2)  ·  Australia (1)  ·  Belgium (1)  ·  Netherlands (1)  ·  United States (1)

Results publications

PMID 36423588, PMID 37926085

NIH funding

2017 (1)